274 related articles for article (PubMed ID: 32333709)
1. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
[TBL] [Abstract][Full Text] [Related]
2. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.
Lam AR; Bert NL; Ho SS; Shen YJ; Tang LF; Xiong GM; Croxford JL; Koo CX; Ishii KJ; Akira S; Raulet DH; Gasser S
Cancer Res; 2014 Apr; 74(8):2193-2203. PubMed ID: 24590060
[TBL] [Abstract][Full Text] [Related]
3. Induction of NKG2D ligand expression on tumor cells by CD8
Hu J; Xia X; Gorlick R; Li S
Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
[TBL] [Abstract][Full Text] [Related]
4. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand.
Nakamura K; Nakayama M; Kawano M; Amagai R; Ishii T; Harigae H; Ogasawara K
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9421-6. PubMed ID: 23690625
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
6. Blockade of NKG2D/NKG2D ligand interaction attenuated cardiac remodelling after myocardial infarction.
Matsumoto K; Obana M; Kobayashi A; Kihara M; Shioi G; Miyagawa S; Maeda M; Sakata Y; Nakayama H; Sawa Y; Fujio Y
Cardiovasc Res; 2019 Mar; 115(4):765-775. PubMed ID: 30307485
[TBL] [Abstract][Full Text] [Related]
7. NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and Kupffer cells in a novel murine natural killer cell-dependent fulminant hepatitis.
Hou X; Zhou R; Wei H; Sun R; Tian Z
Hepatology; 2009 Mar; 49(3):940-9. PubMed ID: 19177594
[TBL] [Abstract][Full Text] [Related]
8. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation.
Zhu S; Phatarpekar PV; Denman CJ; Senyukov VV; Somanchi SS; Nguyen-Jackson HT; Mace EM; Freeman AF; Watowich SS; Orange JS; Holland SM; Lee DA
Blood; 2014 Jul; 124(3):403-11. PubMed ID: 24891320
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3.
Ni L; Wang L; Yao C; Ni Z; Liu F; Gong C; Zhu X; Yan X; Watowich SS; Lee DA; Zhu S
Sci Rep; 2017 Mar; 7():45266. PubMed ID: 28338101
[TBL] [Abstract][Full Text] [Related]
10. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y; Born C; Bléry M; Steinle A
Front Immunol; 2020; 11():960. PubMed ID: 32582150
[TBL] [Abstract][Full Text] [Related]
11. "Acquired" NKG2D Ligand Stimulates NK Cell-mediated Tumor Immunosurveillance.
Wang D; Gu X; Liu X; Liu X; Wang B; Lao F; Fang M
J Immunother; 2019; 42(6):189-196. PubMed ID: 31145234
[TBL] [Abstract][Full Text] [Related]
12. Activating receptor NKG2D targets RAE-1-expressing allogeneic neural precursor cells in a viral model of multiple sclerosis.
Weinger JG; Plaisted WC; Maciejewski SM; Lanier LL; Walsh CM; Lane TE
Stem Cells; 2014 Oct; 32(10):2690-701. PubMed ID: 24898518
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between NKG2DL Expression and Antitumor Effect of Protein-bound Polysaccharide-K in Tumor-bearing Mouse Models.
Konagai A; Yoshimura K; Hazama S; Yamamoto N; Aoki K; Ueno T; Fujioka M; Iijima H; Kato M; Uchida M; Wada T; Inoue M; Asao T; Fuse M; Wada S; Kuramasu A; Kamei R; Takeda S; Yamamoto S; Yoshino S; Oka M; Nagano H
Anticancer Res; 2017 Aug; 37(8):4093-4101. PubMed ID: 28739693
[TBL] [Abstract][Full Text] [Related]
14. Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1.
Champsaur M; Beilke JN; Ogasawara K; Koszinowski UH; Jonjic S; Lanier LL
J Immunol; 2010 Jul; 185(1):157-65. PubMed ID: 20530257
[TBL] [Abstract][Full Text] [Related]
15. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
[TBL] [Abstract][Full Text] [Related]
16. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
[TBL] [Abstract][Full Text] [Related]
17. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
Stojanovic A; Correia MP; Cerwenka A
Front Immunol; 2018; 9():827. PubMed ID: 29740438
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
[TBL] [Abstract][Full Text] [Related]
19. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
20. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
